ARA-290: what it is studied alongside

ARA-290 is a synthetic peptide developed as a non-hematopoietic erythropoietin analogue, also referred to in the literature and trial registries as ARA 290, ARA290, and cibinetide. It belongs to the class of innate repair receptor (IRR) ligands — peptides engineered to engage the IRR without the erythropoietic activity associated with native erythropoietin. The evidence block for this page does not supply a sequence, molecular formula, or molecular weight for the compound, so none are stated here.

The work collected below centres on the innate repair receptor, a heteromeric receptor complex that ARA-290 is described as interacting with briefly to produce anti-apoptotic and anti-inflammatory activity across a range of cells, tissues and organs [2].

Research Studies

ARA-290 and diabetic macular oedema (ARA 290-DMO)

ARA 290-DMO was a prospective, open-label, interventional, single-centre, investigator-led phase II trial designed to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or type 2 diabetes [1]. The primary objective was to determine whether ARA 290, administered at a daily dose of 4 mg subcutaneously for 12 weeks to patients with diabetes mellitus and diabetic macular oedema, would have a beneficial effect on mean change in best corrected visual acuity (BCVA) from baseline to week 12 [1].

This is a human trial record. The evidence block reports the design and the stated objective; it does not report an outcome, so no efficacy claim is made here.

ARA-290 and corneal nerve fiber density in sarcoidosis

A separate study was set up to determine whether ARA 290 is effective in the treatment of the neuropathic symptoms of sarcoidosis [2]. The rationale given in the record is that brief interaction of ARA 290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities in a wide range of cells, tissues and organs, activating repair mechanisms and accelerating healing, including nerve damage that can be associated with sarcoidosis [2].

In that trial, subjects with sarcoidosis and symptoms of small fiber neuropathy were administered ARA 290 or placebo by subcutaneous injection daily for 28 days, with safety monitoring alongside assessment of symptoms [2]. The record describes the compound as a new class of compound at the time of writing [2].

ARA-290 and glycaemic control in prediabetes and type 2 diabetes

A further trial was designed to determine whether ARA 290, described as a non-hematopoietic erythropoietin analogue, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes — impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) — or drug-naive type 2 diabetes [3].

The same study was also set up to evaluate effects of ARA 290 on insulin sensitivity and on serum levels of inflammatory agents such as cytokines [3]. Safety was monitored by following parameters related to hematology, kidney and liver function, and lipid levels [3].

ARA-290 and cognitive and neural processing of emotion in healthy volunteers

Studies on the hormone erythropoietin (EPO) had indicated that EPO may have antidepressant properties, but EPO may cause serious side-effects with repeated administration, such as thrombosis, which limits its usefulness as an antidepressant [4]. ARA290 is described in that record as a peptide that does not have the effects of EPO on blood cells but may still have its effect on brain function [4].

In an attempt to replicate previous findings with a single dose of EPO in healthy volunteers, that study examined the effects of ARA290 on the cognitive and neural processing of emotions in healthy volunteers, with the hypothesis that a single dose of ARA290 would lead to a positive shift in information processing compared to placebo, 7 days post-administration [4].

ARA-290 and the innate repair receptor as the shared mechanistic thread

Across the trial records above, the common mechanistic description is interaction with the innate repair receptor. The sarcoidosis record states that brief interaction of ARA 290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities in myriad cells, tissues and organs throughout the body, activating repair mechanisms and accelerating healing, including nerve damage that can be associated with sarcoidosis [2].

The diabetes record frames the same compound as a non-hematopoietic erythropoietin analogue and asks whether it exerts beneficial effects on blood glucose and insulin secretion [3]. The cognitive record frames it as a peptide that does not have the effects of EPO on blood cells but may still act on brain function [4]. These are three different tissue contexts — nerve, metabolic, and central — built on the same receptor-level premise.

ARA-290 and the separation from erythropoietic activity

The distinction between ARA-290 and native erythropoietin is stated explicitly in the cognitive study record: EPO may cause serious side-effects with repeated administration, such as thrombosis, which limits its usefulness as an antidepressant, whereas ARA290 is a peptide that does not have the effects of EPO on blood cells [4]. The type 2 diabetes record uses the same framing, calling ARA 290 a non-hematopoietic erythropoietin analogue [3].

This is the property that makes the compound a candidate for the non-haematological indications listed on this page. It is also why safety monitoring in the metabolic study included hematology parameters alongside kidney and liver function and lipid levels [3].

ARA-290 and route and duration across the registered studies

The registered studies differ substantially in exposure duration, which is worth noting when reading them side by side. The diabetic macular oedema trial used 4 mg subcutaneously daily for 12 weeks [1]. The sarcoidosis trial used daily subcutaneous injection for 28 days [2]. The cognitive study used a single dose [4].

ARA-290 and the wider regenerative peptide literature

A narrative review of regenerative peptides relevant to chronic pain management summarises current evidence on a set of compounds including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), and glycyl-L-histidyl-L-lysine copper (GHK-Cu) [5]. That review is a reference point for how the regenerative peptide category is being surveyed as a whole rather than a source of ARA-290-specific findings, and it is cited here on that basis only.

ARA-290 and what the evidence on this page does not establish

The records collected here are trial registrations and a review. They describe design, population, route, duration, and stated objectives or hypotheses [1][2][3][4][5]. They do not, in the material available, report completed outcomes for ARA-290 in any of the populations named. No claim about efficacy, potency, or comparative performance is made on this page, and none should be inferred from the existence of a registered study.

Where a mechanism is described — anti-apoptotic and anti-inflammatory activity via the innate repair receptor [2] — that description comes from the framing of the trial record, not from a results dataset presented here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and nothing on this page is medical advice. We do not provide dosing or medical guidance for any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] The Use of ARA290 for the Treatment of Diabetic Macular Oedema — ClinicalTrials.gov
• [2] Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis — ClinicalTrials.gov
• [3] ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) — ClinicalTrials.gov
• [4] Cognitive and Neural Effects of ARA290 — ClinicalTrials.gov
• [5] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management. — europe_pmc